Literature DB >> 9347436

Comparison of respiratory effects of tramadol and oxycodone.

P Tarkkila1, M Tuominen, L Lindgren.   

Abstract

STUDY
OBJECTIVE: To compare the respiratory effects of tramadol and oxycodone.
DESIGN: Placebo-controlled, double-blind randomized study.
SETTING: IV Department of Surgery, Helsinki University Central Hospital. PATIENTS: 36 ASA physical status I and II patients undergoing minor surgery with general anesthesia.
INTERVENTIONS: The respiratory effects of intravenous (i.v.) tramadol 0.6 mg/kg and oxycodone 0.04 mg/kg were compared after induction of anesthesia with propofol and succinylcholine-facilitated endotracheal intubation. Patients spontaneously breathed halothane in 70% nitrous oxide and oxygen via a nonrebreathing valve. The trial drugs or placebo were given after recovery from neuromuscular block.
MEASUREMENTS AND MAIN RESULTS: Inspiratory and expiratory oxygen and end-tidal carbon dioxide concentrations (ETCO2), tidal volume (VT) minute volume of ventilation (VE), and respiratory rate (RR) were recorded by side-stream spirometry with end-tidal halothane of 0.3% for 30 minutes before surgery. Oxycodone caused a significant respiratory depression seen as an increase in the inspiratory-expiratory oxygen difference and ETCO2 and as a decrease in VE and RR. On the contrary, the effect of tramadol were similar to those of placebo. VT was not affected by any study drug.
CONCLUSION: Tramadol was not associated with respiratory depression in the present setting.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9347436     DOI: 10.1016/s0952-8180(97)00147-5

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  14 in total

Review 1.  Implications of opioid analgesia for medically complicated patients.

Authors:  Howard Smith; Patricia Bruckenthal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  Ventilatory responses of healthy subjects to intravenous combinations of morphine and oxycodone under imposed hypercapnic and hypoxaemic conditions.

Authors:  L A Ladd; P C Kam; D B Williams; A W E Wright; M T Smith; L E Mather
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

Review 3.  Clinical pharmacology of tramadol.

Authors:  Stefan Grond; Armin Sablotzki
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 4.  Tramadol: a review of its use in perioperative pain.

Authors:  L J Scott; C M Perry
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 5.  Oxycodone/Ibuprofen combination tablet: a review of its use in the management of acute pain.

Authors:  Vicki Oldfield; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials.

Authors:  John A Zebala; Shawn L Searle; Lynn R Webster; Matt S Johnson; Aaron D Schuler; Dean Y Maeda; Stuart J Kahn
Journal:  J Pain       Date:  2019-04-18       Impact factor: 5.820

7.  Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.

Authors:  William W Stoops; Kevin W Hatton; Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2010-07-28       Impact factor: 4.530

8.  Abuse liability and reinforcing efficacy of oral tramadol in humans.

Authors:  Shanna Babalonis; Michelle R Lofwall; Paul A Nuzzo; Anthony J Siegel; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2012-10-23       Impact factor: 4.492

9.  Antitussive activity of sigma-1 receptor agonists in the guinea-pig.

Authors:  Claire Brown; Malika Fezoui; William M Selig; Carl E Schwartz; James L Ellis
Journal:  Br J Pharmacol       Date:  2003-12-22       Impact factor: 8.739

10.  Options for treating postherpetic neuralgia in the medically complicated patient.

Authors:  Patricia Bruckenthal; Robert L Barkin
Journal:  Ther Clin Risk Manag       Date:  2013-08-19       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.